First Time Loading...

Ovid Therapeutics Inc
NASDAQ:OVID

Watchlist Manager
Ovid Therapeutics Inc Logo
Ovid Therapeutics Inc
NASDAQ:OVID
Watchlist
Price: 2.99 USD -5.08% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

OVID's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. [ Read More ]

The intrinsic value of one OVID stock under the Base Case scenario is 2.58 USD. Compared to the current market price of 2.99 USD, Ovid Therapeutics Inc is Overvalued by 14%.

Key Points:
OVID Intrinsic Value
Base Case
2.58 USD
Overvaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ovid Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling OVID stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Ovid Therapeutics Inc

Provide an overview of the primary business activities
of Ovid Therapeutics Inc.

What unique competitive advantages
does Ovid Therapeutics Inc hold over its rivals?

What risks and challenges
does Ovid Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Ovid Therapeutics Inc recently?

Summarize the latest earnings call
of Ovid Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ovid Therapeutics Inc.

Provide P/S
for Ovid Therapeutics Inc.

Provide P/E
for Ovid Therapeutics Inc.

Provide P/OCF
for Ovid Therapeutics Inc.

Provide P/FCFE
for Ovid Therapeutics Inc.

Provide P/B
for Ovid Therapeutics Inc.

Provide EV/S
for Ovid Therapeutics Inc.

Provide EV/GP
for Ovid Therapeutics Inc.

Provide EV/EBITDA
for Ovid Therapeutics Inc.

Provide EV/EBIT
for Ovid Therapeutics Inc.

Provide EV/OCF
for Ovid Therapeutics Inc.

Provide EV/FCFF
for Ovid Therapeutics Inc.

Provide EV/IC
for Ovid Therapeutics Inc.

Show me price targets
for Ovid Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Ovid Therapeutics Inc?

How accurate were the past Revenue estimates
for Ovid Therapeutics Inc?

What are the Net Income projections
for Ovid Therapeutics Inc?

How accurate were the past Net Income estimates
for Ovid Therapeutics Inc?

What are the EPS projections
for Ovid Therapeutics Inc?

How accurate were the past EPS estimates
for Ovid Therapeutics Inc?

What are the EBIT projections
for Ovid Therapeutics Inc?

How accurate were the past EBIT estimates
for Ovid Therapeutics Inc?

Compare the revenue forecasts
for Ovid Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ovid Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ovid Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ovid Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Ovid Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ovid Therapeutics Inc with its peers.

Analyze the financial leverage
of Ovid Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Ovid Therapeutics Inc.

Provide ROE
for Ovid Therapeutics Inc.

Provide ROA
for Ovid Therapeutics Inc.

Provide ROIC
for Ovid Therapeutics Inc.

Provide ROCE
for Ovid Therapeutics Inc.

Provide Gross Margin
for Ovid Therapeutics Inc.

Provide Operating Margin
for Ovid Therapeutics Inc.

Provide Net Margin
for Ovid Therapeutics Inc.

Provide FCF Margin
for Ovid Therapeutics Inc.

Show all solvency ratios
for Ovid Therapeutics Inc.

Provide D/E Ratio
for Ovid Therapeutics Inc.

Provide D/A Ratio
for Ovid Therapeutics Inc.

Provide Interest Coverage Ratio
for Ovid Therapeutics Inc.

Provide Altman Z-Score Ratio
for Ovid Therapeutics Inc.

Provide Quick Ratio
for Ovid Therapeutics Inc.

Provide Current Ratio
for Ovid Therapeutics Inc.

Provide Cash Ratio
for Ovid Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Ovid Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Ovid Therapeutics Inc?

What is the current Free Cash Flow
of Ovid Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ovid Therapeutics Inc.

Financials

Balance Sheet Decomposition
Ovid Therapeutics Inc

Current Assets 109.6m
Cash & Short-Term Investments 105.8m
Other Current Assets 3.8m
Non-Current Assets 34.4m
Long-Term Investments 17.6m
PP&E 14.7m
Intangibles 183k
Other Non-Current Assets 2m
Current Liabilities 11.5m
Accounts Payable 3.7m
Accrued Liabilities 7.8m
Non-Current Liabilities 44.8m
Other Non-Current Liabilities 44.8m
Efficiency

Earnings Waterfall
Ovid Therapeutics Inc

Revenue
391.7k USD
Operating Expenses
-59.7m USD
Operating Income
-59.3m USD
Other Expenses
6.9m USD
Net Income
-52.3m USD

Free Cash Flow Analysis
Ovid Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

OVID Profitability Score
Profitability Due Diligence

Ovid Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
30/100
Profitability
Score

Ovid Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

OVID Solvency Score
Solvency Due Diligence

Ovid Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

Ovid Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OVID Price Targets Summary
Ovid Therapeutics Inc

Wall Street analysts forecast OVID stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OVID is 7.48 USD with a low forecast of 4.04 USD and a high forecast of 11.55 USD.

Lowest
Price Target
4.04 USD
35% Upside
Average
Price Target
7.48 USD
150% Upside
Highest
Price Target
11.55 USD
286% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

OVID Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

OVID Price
Ovid Therapeutics Inc

1M 1M
0%
6M 6M
-13%
1Y 1Y
-10%
3Y 3Y
-23%
5Y 5Y
+55%
10Y 10Y
-80%
Annual Price Range
2.99
52w Low
2.72
52w High
4.04
Price Metrics
Average Annual Return 16.93%
Standard Deviation of Annual Returns 73.95%
Max Drawdown -83%
Shares Statistics
Market Capitalization 211.4m USD
Shares Outstanding 70 710 000
Percentage of Shares Shorted 4.84%

OVID Return Decomposition
Main factors of price return

What is price return decomposition?

OVID News

Other Videos

Company Profile

Ovid Therapeutics Inc Logo
Ovid Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

211.4m USD

Dividend Yield

0%

Description

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2017-05-05. The firm is focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. The Company’s programs include OV329 (GABA aminotransferase inhibitor), OV350, OV882, and OV815 and OV825. OV329 (GABA aminotransferase inhibitor) is a next-generation GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain’s major inhibitory neurotransmitter, GABA. OV350 is a small molecule that directly activates the KCC2 transporter, which is an important channel in seizure control. OV882, which is a short hairpin RNA (shRNA-551) for Angelman syndrome. OV815, which is a genetic therapy approach for KIF1A-associated neurological disorders.

Contact

NEW YORK
New York City
1460 Broadway Ste 15044
+16466617661.0
http://www.ovidrx.com/

IPO

2017-05-05

Employees

44

Officers

President, CEO & Chairman
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
Principal Financial Officer, Principal Accounting Officer & Chief Business and Financial Officer
Mr. Jeffrey A. Rona
Chief Operating Officer
Mr. Jason Tardio M.B.A.
Senior Director of Investor Relations & Public Relations
Ms. Lora Pike
General Counsel
Mr. Thomas Michael Perone J.D., M.B.A.
Chief Human Resources Officer
Mr. Simon D. Kelner
Show More
Senior Vice President of Global Manufacturing & CMC QA
Dr. Dirk Haasner
Senior Vice President of Regulatory Affairs
Dr. Todd F. Baumgartner M.D., M.P.H.
Senior Vice President of Clinical Development
Dr. Julia Tsai Ph.D.
Chief Strategy Officer
Ms. Meg Alexander
Show Less

See Also

Discover More
What is the Intrinsic Value of one OVID stock?

The intrinsic value of one OVID stock under the Base Case scenario is 2.58 USD.

Is OVID stock undervalued or overvalued?

Compared to the current market price of 2.99 USD, Ovid Therapeutics Inc is Overvalued by 14%.